


**Figure S1.**

1. Expression level of PGM5-AS1 was examined in normal tissues and CRC tissues. **B.** GFI1B expression was upregulated and downregulated using the pcDNA-GFI1B plasmid and si-GFI1B, respectively. **C.** A lentiviral infection system was used to establish a DLD1 cell line stably overexpressing PGM5-AS1. **D.** Three siRNAs targeting different sites (si-PGM5-AS1 1 #, si-PGM5-AS1 2 #, and si-PGM5-AS1 3 #) were designed to silence PGM5-AS1 expression in SW480 cells. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.



**Figure S2.**

**A.** Relationship between PGM5-AS1 expression and PAEP levels in CRC tissues compared with corresponding nontumor tissues. **B.** Relationship between PGM5-AS1 expression and NME1 levels in CRC tissues compared with corresponding nontumor tissues. **C.** Relationship between SRSF3 expression and PAEP levels in CRC tissues compared with corresponding nontumor tissues. **D.** Relationship between PGM5-AS1 expression and miR-423-5p levels in CRC tissues compared with corresponding nontumor tissues. **E.** A miR-423-5p mimic was used to exogenously upregulate the level of miR-423-5p expression, and a miR-423-5p inhibitor was used to downregulate miR-423-5p expression in CRC cell lines. **F.** Relationship between NME1 expression and miR-423-5p levels in CRC tissues compared with corresponding nontumor tissues. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.